Best for Heart Health

Tesamorelin demonstrates strong efficacy for reducing visceral adipose tissue and improving cardiovascular risk markers in HIV-infected patients with lipodystrophy, supported by multiple well-designed RCTs with consistent results. Evidence for direct heart health benefits in non-HIV populations is more limited, though improvements in triglycerides, carotid intima-media thickness, and C-reactive protein suggest cardiovascular benefit.

GnRH agonists and antagonists (including gonadorelin-class compounds) have been extensively studied in prostate cancer patients, with consistent evidence from multiple RCTs and meta-analyses showing that GnRH antagonists (particularly degarelix) are associated with lower cardiovascular event rates compared to GnRH agonists. However, the absolute cardiovascular benefit is modest and mainly demonstrated in specific high-risk populations.

GLP-1 receptor agonists demonstrably improve multiple heart health markers in humans, including blood pressure reduction, lipid profile improvements, and reduced cardiovascular events. Evidence comes from multiple human RCTs and meta-analyses showing consistent, clinically meaningful effects.

Omega-3 fatty acids, particularly EPA and DHA from fish oil, demonstrate strong evidence for improving heart health markers—primarily triglyceride reduction and HDL cholesterol increases. Multiple large meta-analyses and RCTs confirm efficacy, though results vary by formulation (EPA-only vs. EPA+DHA mixtures) and population.

Magnesium supplementation reduces blood pressure in hypertensive populations and those with low baseline magnesium, with consistent effects across multiple meta-analyses and RCTs. Efficacy is proven in humans for blood pressure reduction, though effects are modest (2-8 mm Hg systolic reduction) and most pronounced in specific subgroups.

Berberine demonstrates strong evidence for improving multiple cardiovascular and metabolic risk factors in humans, with consistent benefits across multiple well-designed RCTs and meta-analyses. Primary evidence supports reductions in triglycerides, LDL cholesterol, total cholesterol, fasting glucose, and blood pressure, with effect sizes of clinical relevance.

Curcumin demonstrates strong evidence for cardiovascular and metabolic benefits in humans, with consistent improvements in blood lipid profiles, blood pressure, endothelial function, and inflammatory markers across multiple high-quality meta-analyses and RCTs.

CoQ10 demonstrates strong evidence for improving cardiovascular health markers, particularly blood pressure reduction and endothelial function. Multiple meta-analyses and RCTs show consistent, clinically meaningful improvements in heart health parameters, though effect sizes vary by outcome and dosage.

Alpha-lipoic acid demonstrates strong evidence for improving cardiometabolic risk factors in humans, particularly insulin resistance, blood glucose, triglycerides, and total cholesterol. Multiple meta-analyses and RCTs show consistent, clinically meaningful benefits, though effects on blood pressure and HDL cholesterol remain inconsistent.

Melatonin supplementation demonstrates consistent, clinically meaningful benefits for multiple heart health parameters in humans, particularly blood pressure reduction and cardiometabolic risk factor improvement. Evidence is supported by multiple meta-analyses of RCTs showing robust effects, though sample sizes in individual trials are often modest.

Black seed oil demonstrates consistent, clinically meaningful improvements in cardiovascular risk factors across multiple human RCTs and large meta-analyses. Evidence supports benefits for blood pressure, cholesterol, and glucose control in at-risk populations, though effect sizes are modest.

Aged garlic extract demonstrates consistent, clinically meaningful improvements in blood pressure and cardiovascular calcification in human RCTs. Multiple meta-analyses confirm efficacy for hypertension management, particularly at doses >1200 mg/day, with effect sizes of 4-5 mmHg systolic and 1-2 mmHg diastolic reductions.

Psyllium husk demonstrates strong, consistent evidence for reducing LDL cholesterol and improving lipid profiles in humans, with multiple RCTs and meta-analyses confirming clinically meaningful reductions. Additional benefits on blood pressure, glycemic control, and weight loss support cardiovascular health, though blood pressure effects are modest.

Spirulina demonstrates strong evidence for improving multiple cardiovascular risk factors in humans, with consistent benefits across blood pressure, lipid profiles, and glucose control documented in multiple RCTs and meta-analyses. Effects are modest but clinically meaningful, particularly in hypertensive and overweight populations.

Intravenous iron supplementation in heart failure patients with iron deficiency reduces hospitalizations and improves exercise capacity, supported by multiple meta-analyses of RCTs. Oral iron shows minimal clinical benefit despite correcting iron markers.

Pycnogenol demonstrates consistent, clinically meaningful improvements in multiple cardiovascular risk factors across numerous human RCTs and meta-analyses, with proven effects on blood pressure, glucose control, and endothelial function. However, effects on lipid profiles remain inconsistent, and long-term efficacy data are limited.

Grape seed extract demonstrates clinically meaningful blood pressure reduction and improvements in cardiovascular risk markers across multiple human RCTs, with consistent effects on diastolic blood pressure and heart rate. Evidence is strong but limited by modest effect sizes and heterogeneity in study populations and dosing protocols.

Whey protein supplementation demonstrates consistent, clinically meaningful improvements in cardiometabolic health markers when combined with exercise or in controlled dietary interventions. Multiple high-quality RCTs show benefits for blood pressure, lipid profiles, and inflammatory markers, though individual effects are modest.

L-Arginine supplementation has demonstrated consistent blood pressure-lowering effects in multiple human RCTs and meta-analyses, with reductions of 5-6 mmHg systolic and 2-3 mmHg diastolic pressure. Efficacy is proven for hypertension management, though effects on acute myocardial infarction outcomes and endothelial function markers show mixed or null results.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, demonstrates strong evidence for cardiovascular and cardiometabolic benefits in humans. Multiple RCTs and meta-analyses show significant reductions in blood pressure, lipids, body weight, and cardiovascular event risk in individuals with obesity and/or type 2 diabetes.

Tirzepatide demonstrates strong cardiovascular benefits in people with type 2 diabetes and obesity, reducing major adverse cardiovascular events (MACE) by 13-41% across multiple randomized controlled trials. Evidence is robust but primarily in diabetic/obese populations; effects in general heart health populations are not yet established.

Dulaglutide, a GLP-1 receptor agonist, has demonstrated consistent cardiovascular benefits in multiple large human RCTs, reducing major adverse cardiovascular events (MACE), cardiovascular death, and stroke in patients with type 2 diabetes. Effects on heart health are proven in humans with high-quality evidence.

Exenatide demonstrates strong cardiovascular benefits in type 2 diabetes patients, with multiple large RCTs and meta-analyses showing reduced major adverse cardiovascular events (MACE) and improved vascular function. Evidence is primarily from human trials in diabetic populations.

Lixisenatide shows cardiovascular safety in patients with type 2 diabetes and recent acute coronary syndrome, demonstrating noninferiority to placebo. However, it does not demonstrate superiority for heart health outcomes compared to other GLP-1 receptor agonists, which show greater cardiovascular benefits.

Cinnamon supplementation has been shown in multiple human RCTs and meta-analyses to improve several cardiovascular risk factors, including blood pressure, lipid profiles, and glucose control. Effects are consistent and clinically meaningful, though individual studies vary in sample size and duration.

Beetroot supplementation has strong evidence from multiple human RCTs showing it reduces blood pressure and improves vascular endothelial function in adults, particularly in older and hypertensive populations. Effects are consistent but modest in magnitude.

Creatine monohydrate shows promise for certain cardiovascular and endothelial functions in humans, with evidence of improved vascular function and modest blood pressure/metabolic benefits in older adults. However, evidence remains limited by small sample sizes, short durations, and inconsistent findings across studies—efficacy is probable but not conclusively proven for heart health as a primary outcome.

Ashwagandha shows probable but not conclusive benefits for heart health, with human evidence limited to small RCTs demonstrating improvements in heart rate variability, cardiorespiratory endurance, and lipid profiles. No large, well-powered human trials directly measuring cardiac outcomes exist.

TB-500 shows moderate evidence for heart health benefits based on human RCTs demonstrating improved cardiac function and reduced adverse remodeling after myocardial infarction, though most evidence comes from animal studies.

MOTS-c shows probable benefit for heart health based on multiple human observational studies demonstrating reduced levels in acute coronary syndrome and associations with endothelial dysfunction and cardiac events. However, evidence remains limited to observational designs with small samples; no large RCTs have proven efficacy of MOTS-c supplementation for preventing or treating heart disease.

SS-31 (elamipretide) shows promising mitochondrial-protective effects in heart failure models with some positive human trial results, but evidence remains mixed with several large human RCTs failing to meet primary endpoints. Efficacy is probable but not conclusively proven.

Sermorelin (a GHRH agonist) shows consistent beneficial effects on cardiac structure and function in animal models of heart failure and myocardial infarction, with mechanistic plausibility demonstrated in large-animal studies. However, evidence in humans is limited to a single small metabolic study with no direct cardiac endpoints, making efficacy in human heart disease probable but not conclusively proven.

LL-37 shows probable benefit for heart health based on human observational studies demonstrating associations between higher LL-37 levels and reduced cardiovascular events after myocardial infarction, plus mechanistic evidence from animal studies. However, evidence remains limited to observational designs and animal models with no large-scale human RCTs confirming efficacy.

Hexarelin demonstrates probable efficacy for heart health in humans based on multiple small RCTs showing improved cardiac function, but evidence is limited by small sample sizes, short treatment durations, and lack of independent replication. Animal studies consistently support cardioprotective effects across multiple mechanisms.

Humanin shows probable cardioprotective effects in human studies, with lower circulating levels associated with coronary artery disease and major adverse cardiac events. However, the evidence relies primarily on observational studies and a limited number of human RCTs, with inconsistent findings in some contexts.

Thymalin shows probable benefits for heart health in humans based on observational studies and one RCT, with reported reductions in cardiovascular disease incidence and improved hemodynamic parameters. However, evidence is limited by small sample sizes, lack of independent replication, and reliance on older Russian studies with modest methodological detail.

ARA-290 shows promise for heart health in animal models and early human studies, with evidence of reduced cardiac inflammation, improved heart function, and endothelial protection. However, human evidence remains limited to small studies and observational work; no large-scale human RCTs specifically measuring cardiac outcomes have been published.

Cerebrolysin shows probable efficacy for heart health primarily through indirect cerebrovascular benefits in stroke patients, but direct cardiac effects are not demonstrated. Evidence comes from multiple human RCTs focused on stroke outcomes and cognitive function related to vascular disease, with limited direct relevance to primary cardiac health.

Vitamin D3 shows probable but inconsistent benefits for heart health, with strongest evidence for endothelial function improvement and modest blood pressure reductions in specific populations. However, multiple meta-analyses show mixed results and effects vary substantially by dose, duration, baseline status, and population.

Zinc supplementation shows probable benefits for cardiovascular risk factors including blood lipids, glucose control, and inflammation in humans, supported by multiple meta-analyses of RCTs. However, direct evidence of improved heart health outcomes (e.g., reduced cardiac events, improved ejection fraction) is limited to small pilot studies and observational data.

Quercetin demonstrates probable efficacy for heart health, primarily through modest reductions in systolic blood pressure and some improvements in lipid profiles and oxidative stress markers in humans. However, evidence is limited by inconsistent effects across studies, small sample sizes, and mixed results on key cardiometabolic outcomes.

Resveratrol shows moderate evidence for heart health benefits, primarily through improvements in endothelial function and modest reductions in some cardiometabolic risk factors. However, effects on blood pressure and lipid profiles are inconsistent across studies, and most human trials are small with short durations.

NMN shows probable but not conclusive efficacy for heart health in humans, with modest improvements in blood pressure and some cardiovascular markers in limited RCTs, but effects are small and not yet independently replicated at scale.

Probiotics show probable benefits for heart health markers including blood lipid improvement and blood pressure reduction in type 2 diabetes patients, supported by multiple meta-analyses and RCTs. However, evidence for direct cardiovascular outcomes is limited, and effects on key markers like TMAO and lipid profiles are inconsistent across studies.

Vitamin K2 (menaquinone-7) shows probable benefit for arterial stiffness in specific populations, but evidence for broader cardiovascular protection remains inconclusive. Multiple human RCTs demonstrate improvements in pulse wave velocity and vascular markers in kidney disease and post-menopausal women, yet trials in general populations and patients with established calcification show null or marginal effects.

Maca shows probable benefits for blood pressure reduction and cardiovascular metabolic markers in humans, supported by 2 small RCTs and several observational studies, but efficacy remains incompletely proven due to small sample sizes and limited replication.

Elderberry shows plausible cardiovascular benefits through in vitro and mechanistic studies, particularly regarding endothelial function and foam cell formation, but human evidence remains limited to a single 12-week RCT showing no significant changes in CVD biomarkers. Efficacy in humans is suggested but not conclusively proven.

Green tea extract (particularly EGCG) shows probable benefits for heart health, with consistent evidence for blood pressure reduction and lipid improvements in human studies, but efficacy is limited by small sample sizes, short study durations, and mixed results across metabolic outcomes.

Fenugreek demonstrates probable efficacy for improving several cardiometabolic risk factors in humans, particularly reducing total cholesterol, LDL, and triglycerides, with consistent results across multiple human trials. However, evidence quality is limited by small sample sizes, short durations, and heterogeneous study designs.

Vitamin C shows probable benefits for endothelial function and some cardiovascular risk factors in humans, but large RCTs have not confirmed benefits on actual cardiovascular disease outcomes. Evidence is mixed: acute/short-term studies demonstrate endothelial improvements, but chronic supplementation trials show inconsistent results.

B vitamin supplementation shows probable benefits for cardiovascular health, particularly for stroke prevention through homocysteine reduction, but evidence is inconsistent and efficacy is not conclusively proven across all populations or outcomes.

Vitamin B12 supplementation has demonstrated efficacy for lowering homocysteine levels (a cardiovascular risk marker) in multiple human studies, particularly when combined with folic acid. However, evidence for direct improvement in clinical heart health outcomes remains mixed, with benefit heavily dependent on renal function status and B12 form used.

Vitamin E supplementation shows modest benefits for some cardiovascular markers (endothelial function, systolic blood pressure, arterial compliance) based on multiple human RCTs, but effects are inconsistent across studies and modest in magnitude. Efficacy is probable but not conclusive.

Selenium shows probable but not conclusive benefits for heart health, with observational studies suggesting cardiovascular protection at optimal blood levels (55-145 μg/L), but randomized controlled trials generally fail to demonstrate clear clinical benefit from supplementation in selenium-replete populations.

Chromium supplementation shows modest, inconsistent benefits for cardiovascular risk factors in humans, primarily through improvements in glucose metabolism and modest lipid changes. Evidence is moderate quality with mixed results across studies.

Biotin shows probable but not conclusive benefits for heart health, primarily through improvements in triglycerides and cholesterol in patients with type 2 diabetes and hypertriglyceridemia. Human evidence is limited to 4 RCTs with small-to-moderate sample sizes and relatively short intervention periods.

Urolithin A shows probable efficacy for heart health in humans through mitochondrial quality improvement and endothelial function enhancement, but evidence is limited to small RCTs with mixed results on clinical outcomes. Most compelling data comes from mechanistic animal studies and indirect vascular function markers rather than direct cardiac function improvements.

Astaxanthin shows probable benefit for heart health, particularly in reducing inflammation and oxidative stress markers, with emerging evidence for improving cardiac function in heart failure patients. However, effects on traditional cardiovascular risk factors (blood pressure, lipid profiles) are inconsistent, and most human studies are small, short-duration, or observational.

Glutathione supplementation shows probable benefit for heart health in humans, primarily through improvements in endothelial function and blood pressure reactivity. However, evidence remains limited to small human RCTs with short durations, and results are inconsistent across different outcome measures.

TUDCA shows probable efficacy for heart health through endothelial protection and anti-apoptotic effects in humans, supported by one small RCT and multiple animal studies, but evidence remains limited by few human trials and small sample sizes.

Nattokinase shows probable efficacy for heart health based on multiple human RCTs demonstrating modest reductions in blood pressure, improvements in lipid profiles, and antithrombotic effects, but a large rigorous trial found null effects on subclinical atherosclerosis progression, and effect sizes are inconsistent across studies.

Beta-glucans show probable efficacy for heart health through modest cholesterol-lowering effects demonstrated in multiple human studies, but efficacy is inconsistent and clinically modest. One recent RCT found no significant benefit, creating uncertainty about real-world effectiveness.

Reishi shows probable benefits for heart health through lipid profile improvement and antioxidant mechanisms, supported by multiple human RCTs and consistent animal studies. However, evidence remains limited by small sample sizes, short intervention periods, and lack of large-scale replication.

Epicatechin shows probable benefit for heart health, particularly for blood pressure reduction and endothelial function, supported by multiple human RCTs and meta-analyses. However, effect sizes are modest, results are inconsistent across populations, and some well-designed trials show null effects, preventing a higher evidence tier.

Pomegranate extract shows probable but not conclusive benefits for heart health in humans, with consistent evidence for blood pressure reduction and inflammatory marker improvements, but effect sizes are modest and most studies are small with limited long-term follow-up.

Olive leaf extract shows probable efficacy for heart health through modest improvements in blood pressure, lipid profiles, and glucose metabolism in humans. However, evidence is limited to small-to-moderate RCTs with short durations and inconsistent effect sizes across studies.

Bromelain shows probable efficacy for heart health through anti-inflammatory, antithrombotic, and cardioprotective mechanisms, demonstrated in multiple human studies and consistently replicated animal models. However, evidence remains moderate due to small sample sizes in human trials, limited long-term follow-up data, and most positive findings coming from combination supplements rather than bromelain monotherapy.

Stinging nettle shows probable efficacy for heart health markers in humans, primarily through improvements in blood pressure, triglycerides, and inflammatory markers in type 2 diabetes patients. However, evidence remains limited to small RCTs and observational studies with modest sample sizes.

Tribulus terrestris shows probable efficacy for heart health, primarily through blood pressure reduction and lipid profile improvement demonstrated in multiple human trials. However, evidence is limited by small sample sizes, short durations, and lack of independent replication across studies.

Lemon balm shows probable efficacy for heart health, particularly for blood pressure reduction and lipid management in humans, supported by multiple RCTs. However, evidence quality is limited by small sample sizes, short durations, and inconsistent effects across cardiometabolic markers.

Methylene blue shows probable efficacy for treating refractory shock and vasoplegic syndrome in cardiac and critical care settings, with consistent positive hemodynamic effects reported across multiple human case reports and observational studies. However, evidence remains limited to small sample sizes and non-randomized designs without robust RCT confirmation.

Astragalus membranaceus shows probable efficacy for heart health through multiple human studies and meta-analyses demonstrating improvements in cardiac function, reduced myocardial enzymes, and protective effects against myocardial injury. However, evidence is limited by small sample sizes, short durations, and lack of large-scale, independently replicated RCTs.

Betaine supplementation reliably lowers homocysteine levels in humans, a cardiovascular risk factor, but evidence for direct heart health benefits is mixed. Most human studies show betaine does not improve blood pressure, triglycerides, or inflammatory markers, and higher doses may increase total and LDL cholesterol—potentially offsetting homocysteine benefits.

Ginkgo biloba extract shows probable cardiovascular benefits in humans, particularly for myocardial ischemia-reperfusion injury protection and blood rheology improvements in diabetic patients, but efficacy is not conclusively proven due to limited large-scale RCT data and mixed results across cardiovascular endpoints.

Panax ginseng shows probable benefits for cardiovascular health based on multiple human studies and consistent mechanistic evidence, but efficacy is not yet conclusively proven. Most human evidence comes from small trials or observational designs, with limited large-scale RCT confirmation.

PQQ shows probable efficacy for heart health based on multiple human RCTs and consistent animal studies demonstrating reductions in infarct size, improved cardiac function, and anti-inflammatory effects. However, human evidence is limited to small sample sizes (n≤29) and short durations, preventing a higher tier classification.

L-theanine shows probable benefits for heart health through antioxidant and stress-reduction mechanisms, supported by multiple human studies and mechanistic research. However, evidence remains limited by small sample sizes, short durations, and lack of independent replication of key findings.

Acetyl-L-carnitine shows probable benefit for heart health in humans, supported by 4 RCTs and multiple observational studies demonstrating improvements in vascular function, blood pressure, and cardiac parameters. However, evidence remains moderate due to small sample sizes, inconsistent results across studies, and limited replication of findings by independent groups.

Glycine shows probable benefit for heart health based on large observational studies and consistent animal evidence, but human RCT evidence is limited. Elevated glycine levels correlate with reduced coronary artery disease risk, though causality remains incompletely established.

GABA demonstrates probable efficacy for blood pressure reduction in humans based on 3 small RCTs, with consistent systolic BP reductions of 0.75-17.4 mmHg. However, evidence remains limited by small sample sizes (n<40), short intervention periods, and lack of independent replication in larger studies.

L-Citrulline shows probable benefit for heart health, particularly for blood pressure reduction and endothelial function in specific populations, but evidence is mixed with inconsistent effects across studies and mostly small sample sizes.

HMB supplementation shows probable benefits for cardiac-relevant outcomes including vascular endothelial function, inflammatory markers, and postoperative recovery in cardiac surgery patients, but evidence is limited by small sample sizes, short durations, and mixed results on lipid profiles—the primary cardiovascular risk factor.

Taurine demonstrates probable cardiovascular benefits for heart health based on multiple human RCTs and meta-analyses, showing consistent reductions in blood pressure and improvements in cardiac function parameters. However, evidence remains limited by small individual study sample sizes and relatively short treatment durations.

Cagrilintide as part of CagriSema (combined with semaglutide) shows moderate evidence for cardiovascular benefits in adults with obesity, primarily through blood pressure reduction and weight loss. Direct cardiovascular efficacy data in humans remains limited, with most evidence indirect through metabolic improvements.

Lanreotide demonstrates probable benefits for heart health in acromegaly patients, with multiple human studies showing improvements in left ventricular mass, cardiac function, and exercise tolerance. However, evidence is limited to acromegaly-specific populations and results are not universally consistent across all cardiac parameters.

Octreotide shows moderate evidence for heart health benefits, primarily in acromegaly patients where it reduces heart rate, blood pressure, and cardiac structural changes. Evidence is limited to small human studies and one meta-analysis; efficacy for general cardiac health or other heart conditions is not established.

Setmelanotide is a melanocortin-4 receptor agonist that reduces body weight and metabolic syndrome risk in patients with specific rare genetic obesity syndromes, but evidence for general heart health benefits remains limited and indirect.

Survodutide, a dual glucagon/GLP-1 receptor agonist, is under investigation for cardiovascular safety in people with obesity, but efficacy data for heart health outcomes are limited to one ongoing trial design paper without efficacy results.

NAD+ precursors show probable but not conclusive efficacy for heart health in humans. Two small RCTs demonstrate improvements in blood pressure and lipid profiles, while extensive preclinical evidence supports cardiovascular benefits, but human trial data remains limited and mixed.

Vitamin B1 (thiamine) supplementation shows probable but inconsistent benefits for heart health, particularly in heart failure patients. While multiple human studies suggest potential improvements in ejection fraction and heart failure outcomes, recent meta-analyses reveal conflicting results with no significant effects on key cardiac measures in larger pooled analyses.

Vitamin B2 (riboflavin) shows probable efficacy for heart health specifically in individuals carrying the MTHFR 677TT genetic variant, with multiple RCTs demonstrating meaningful blood pressure reductions of 5–13 mmHg systolic. Evidence is less clear for the general population without this specific genotype.

Vitamin B5 shows a probable benefit for heart health based on one human observational study finding lower coronary heart disease risk at adequate plasma levels, but evidence is limited to a single case-control study with no RCTs to confirm causation.

Vitamin B6 shows moderate evidence for heart health benefits, primarily through homocysteine reduction and improvements in endothelial function and blood pressure. However, most human trials are small and results are inconsistent—notably, large RCTs testing homocysteine-lowering therapy have failed to show clear cardiovascular outcome improvements.

Folate supplementation shows modest benefits for heart health primarily through homocysteine reduction and endothelial function improvement in specific populations, but large RCTs have not demonstrated clear reductions in major cardiovascular events.

Luteolin shows probable benefit for heart health based on multiple human observational studies and consistent animal research, but evidence remains limited to observational data and animal models with only one animal RCT-equivalent study. Human RCT evidence is essentially absent.

Vitamin K1 shows probable benefits for heart health, particularly in reducing cardiovascular calcification progression in dialysis patients and lowering aortic stenosis risk with higher dietary intake. However, evidence from general population RCTs is limited and inconsistent regarding most cardiovascular outcomes.

Lycopene shows probable benefits for heart health markers, particularly in reducing triglycerides and improving endothelial function, but evidence is limited to small human trials with inconsistent effects across cardiovascular risk factors. Meta-analyses confirm modest improvements in LDL-cholesterol, blood pressure, and flow-mediated dilation, but clinical significance remains unclear.

Apple cider vinegar shows modest improvements in some cardiometabolic markers (fasting blood glucose, HbA1c, total cholesterol) in human studies, but effects are small and inconsistent across other heart health parameters. Evidence is limited to observational studies and meta-analyses of small RCTs; no large, well-controlled human trials exist.

Black pepper (piperine) shows probable benefits for heart health markers, particularly when combined with curcumin, with consistent improvements in triglycerides, cholesterol, and blood pressure demonstrated in multiple human trials. However, evidence is limited by small sample sizes and short intervention periods, preventing a higher tier rating.

Moringa shows probable but not conclusive benefits for heart health, with modest effects on blood pressure and lipid profiles in humans, though most human evidence is limited to small studies. Animal data consistently supports cardiovascular benefits, but human RCT evidence is sparse and mixed.

BPC-157 shows promising cardiovascular effects in animal studies, particularly for protecting heart function and blood vessels during stress conditions, but lacks human efficacy data for heart health specifically.

GHK-Cu shows consistent protective effects in animal models of lung injury and tissue damage through anti-inflammatory and antioxidant mechanisms, but no rigorous human efficacy trials exist for heart health specifically. Evidence is emerging but not proven in humans.

Epithalon shows plausible but unproven effects on heart health through gene expression modulation in animal models. No human clinical trials exist to demonstrate efficacy for cardiovascular outcomes.

DSIP shows plausible cardiac effects in animal models, including antiarrhythmic activity and modulation of cardiac autonomic regulation, but efficacy in humans has not been demonstrated. Only 1 human RCT exists and it does not directly assess heart health outcomes.

KPV shows promise for vascular calcification and inflammation-related cardiovascular conditions in animal models, but no human clinical trials have been conducted. Evidence is limited to mechanistic studies and animal disease models, making human efficacy unproven.

Thymosin Alpha-1 has not been demonstrated to improve heart health outcomes in humans. While animal studies suggest potential antiatherogenic and antioxidant effects, and one ongoing RCT (PANDA II) is evaluating its role in acute aortic dissection surgery, no completed human trials directly measuring cardiac outcomes have been published.

Kisspeptin shows plausible cardiovascular and metabolic benefits in animal models and preliminary human studies, but efficacy for heart health is not yet proven in humans. Most evidence comes from reproductive/metabolic contexts with indirect relevance to cardiac outcomes.

GHRP-2 shows cardioprotective effects in animal models of heart failure, ischemia/reperfusion injury, and cardiomyopathy, but no human RCTs have evaluated efficacy for heart health. Evidence is limited to small animal studies and observational human data on unrelated conditions.

GHRP-6 shows promising cardioprotective effects in animal models and isolated cell studies, with consistent mechanisms involving oxidative stress reduction and improved cardiac function. However, no human RCTs demonstrating clinical efficacy in heart health have been published; evidence remains preclinical.

Melanotan 2 shows emerging cardiovascular effects primarily through central melanocortin receptor activation in animal models, with demonstrated effects on blood pressure, heart rate, and vascular function. However, no human RCT evidence supports efficacy for heart health, and effects are mixed—some beneficial (anti-inflammatory, endothelial function) and some potentially unfavorable (increased sympathetic activity, blood pressure elevation).

Follistatin 344 shows promise as a myokine that responds to exercise and may influence cardiometabolic markers, but evidence is limited to mechanistic studies and a single small human RCT. No direct evidence demonstrates that follistatin 344 supplementation improves heart health outcomes.

GDF-11 shows cardioprotective effects in animal models and mechanistic studies, but human evidence is limited to observational studies with mixed findings. One large human RCT found that systemic GDF-11 elevation actually worsened myocardial infarction outcomes, contradicting the therapeutic hypothesis.

FOXO4-DRI shows plausible mechanisms for improving vascular health by clearing senescent endothelial cells in animal models, but efficacy has not been demonstrated in humans. One observational human study found high senescence markers in pulmonary hypertension patients and used FOXO4-DRI as an intervention, but results regarding actual clinical outcomes are not clearly reported in the available abstract.

VIP shows plausible cardiovascular benefits in animal models and small human studies, particularly for myocardial fibrosis and pulmonary hypertension, but human efficacy remains unproven with no large-scale RCTs demonstrating clinical benefit.

Vilon shows plausible mechanisms for cardiovascular support based on animal studies and gene expression changes, but no human clinical trials exist to demonstrate efficacy for heart health in humans.

Ibutamoren (MK-677) increases growth hormone and IGF-1 levels in humans, but evidence for direct cardiac or heart health benefits is weak and conflicting. One major RCT was terminated early due to safety signals of congestive heart failure.

IGF-1 LR3 shows promise for cardiac growth and coronary vascular development in fetal animal models, but all evidence is limited to animal studies with no human trials demonstrating efficacy for heart health in living patients.

MGF shows plausible cardioprotective effects in animal models and cell culture studies, with some promising mechanistic data suggesting it may reduce apoptosis and improve cardiac function after myocardial infarction. However, no rigorous human RCTs exist to prove efficacy in heart health.

Oxytocin's effects on heart health are plausible based on one human protocol study suggesting stress-buffering cardiovascular effects, but no completed human trials demonstrating actual efficacy for cardiac outcomes have been published. Animal studies show metabolic and physiological changes but do not directly measure heart health endpoints.

Cortexin has been studied in several human trials and animal models, primarily for stroke recovery and cognitive outcomes rather than direct cardiac health benefits. Evidence for heart health specifically is indirect and limited, with no dedicated human RCTs demonstrating efficacy for cardiovascular endpoints.

NAC has demonstrated antioxidant and anti-inflammatory mechanisms relevant to heart health in both animal and human studies, but human evidence for direct cardiac benefit remains limited and mixed. Efficacy in preventing or improving heart disease outcomes in humans has not been conclusively proven.

Collagen peptides show plausible mechanisms for heart health through effects on extracellular matrix and fibrosis markers, but direct evidence of cardiovascular benefit in humans is limited. Most data comes from animal studies, mechanistic research, and indirect biomarker associations rather than clinical outcomes.

Tongkat Ali shows potential mechanisms for cardiovascular benefit in animal and in-vitro studies, but human evidence is limited to one small RCT showing no improvement in lipid parameters, and one case report of atrial flutter. Efficacy for heart health in humans is not proven.

Boron shows promise for heart health through improvements in cardiac function and lipid metabolism in animal models, but human evidence is limited to small studies and observational data with inconsistent findings on cardiovascular risk factors.

Milk thistle shows plausible cardiovascular benefits through antioxidant and lipid-modulating mechanisms in animal and limited human studies, but efficacy for heart health is not proven in humans. Most evidence comes from animal models or mechanistic reviews rather than rigorous human trials.

Rhodiola rosea shows plausible cardiovascular benefits in animal and mechanistic studies, particularly via salidroside-mediated antioxidant and anti-inflammatory pathways. However, human evidence remains limited and mixed: only 6 human RCTs exist, most with small samples and short durations, with inconsistent effects on direct cardiac outcomes.

Glucosamine + Chondroitin has not been proven effective for heart health in rigorous human trials. Observational studies suggest cardiovascular benefits, but these findings are likely explained by selection bias rather than true efficacy.

Iodine supplementation shows plausible benefit for heart health primarily through thyroid function normalization and cholesterol reduction in iodine-deficient populations, but human evidence is limited to small RCTs and observational studies with inconsistent relevance to general cardiovascular health.

Copper supplementation shows plausible mechanisms for heart health through antioxidant enzyme activation and angiogenesis promotion, but human evidence for clinically meaningful cardiovascular benefits is weak and inconsistent. Most positive findings come from animal studies or mechanistic observations rather than proven efficacy in humans.

Fisetin shows plausible cardiovascular benefits through multiple mechanistic pathways in animal and early human studies, but efficacy in humans remains unproven. Only one human RCT exists (STOP-Sepsis, ongoing), and most evidence comes from animal models and observational studies of related conditions.

Spermidine shows promising cardiovascular benefits in animal models and mechanistic human studies, but efficacy in humans remains unproven. The single human RCT demonstrated safety at 40 mg/day but found no changes in circulating polyamine levels or standard cardiovascular markers.

Sulforaphane shows promise for heart health through Nrf2 activation and antioxidant mechanisms in animal and mechanistic studies, but human evidence is limited to small trials and observational data with mixed results, including one study reporting cardiac contractility impairment.

Boswellia shows promise for heart health through improvements in lipid profiles and potential cardioprotective effects in cell models, but evidence is limited to one small human RCT with negative results, animal studies, and in-vitro data. No robust human clinical trials demonstrate efficacy for cardiovascular outcomes.

Two human RCTs tested shilajit for metabolic and cardiovascular markers, but neither study provides clear, isolated efficacy data for shilajit alone on heart health outcomes. Study 1 combined shilajit with chromium and phyllanthus in a complex intervention; Study 2 measured skin gene expression and perfusion rather than direct cardiac or lipid endpoints.

Colostrum has been studied for heart health primarily in the context of cardiovascular risk factors (cholesterol, triglycerides, blood glucose) and infection prevention in high-risk cardiac patients, but evidence is limited to small human studies and lacks robust cardiovascular outcome data. One human RCT reported colostrum reduced flu incidence in high-risk cardiovascular subjects, but direct cardiac efficacy trials are absent.

Cordyceps shows plausible cardiovascular benefits in animal models and mechanistic studies, but human evidence is extremely limited. Only 2 small human studies exist, neither directly measuring heart health outcomes, making efficacy for this goal unproven.

Chaga shows emerging promise for heart health based on multiple animal studies demonstrating improvements in lipid profiles, glucose control, and myocardial protection. However, there is essentially no human RCT evidence—only one small human case report describing adverse kidney effects from excessive consumption.

Apigenin shows promise for heart health through animal studies and in vitro research demonstrating improvements in endothelial function, oxidative stress reduction, and anti-inflammatory effects. However, no human clinical trials exist, so efficacy in humans remains unproven.

Pterostilbene shows plausible cardiovascular benefits in animal models and mechanistic studies, but human evidence is limited to one small RCT with mixed results (blood pressure reduction but LDL increase). Efficacy for heart health in humans remains unproven.

MSM shows emerging promise for heart health, with one small RCT demonstrating elevated HDL cholesterol after 16 weeks of supplementation in overweight/obese adults. However, efficacy is not yet proven—the single relevant human study is small (n=22), lacks independent replication, and does not demonstrate effects on other cardiac risk factors.

Mucuna pruriens shows plausible antihypertensive and ACE-inhibitory effects in animal and in-vitro studies, with one small human RCT suggesting cardiovascular safety. However, no human clinical trials have demonstrated efficacy for heart health outcomes, and current evidence is insufficient to prove cardiovascular benefit.

Ecdysterone shows potential cardiovascular benefits in animal models, with mechanistic evidence suggesting anti-inflammatory and blood pressure-lowering effects. However, no human RCTs directly evaluating cardiac outcomes exist, limiting proof of efficacy in humans for heart health.

Turkesterone shows plausible cardiovascular and stress-protective effects in animal models, but no human clinical trials exist. Evidence is limited to rodent studies demonstrating hepatoprotective and stress-adaptive properties.

Cistanche tubulosa and its bioactive compounds show consistent vasorelaxant and cardioprotective effects in animal models through NO-cGMP and anti-inflammatory pathways, but clinical efficacy in humans has not been demonstrated. Only 2 human RCTs exist, neither specifically measuring heart health endpoints.

Valerian root shows plausible cardiovascular effects in limited human studies and animal models, but efficacy for heart health is not conclusively proven. Evidence is primarily indirect (sleep improvement, autonomic tone changes) rather than direct cardiac benefit.

Kava shows preliminary promise for heart health through improved vagal cardiac control in anxiety disorder patients, but evidence is limited to one small human RCT (n=13) with mixed results and lacks independent replication. Mechanism involves vascular relaxation via calcium channel inhibition, demonstrated in animal tissue studies.

Passionflower (Passiflora incarnata) shows anxiolytic effects comparable to midazolam in dental surgery contexts, but evidence for direct heart health benefits is absent. The studies focus on anxiety control as a secondary measure of cardiovascular stability, not on treating cardiovascular disease or improving cardiac function.

Schisandra chinensis shows plausible mechanisms for cardiovascular support through anti-inflammatory and antioxidant pathways, but human evidence for heart health specifically remains very limited. Only 3 human studies exist, none directly measuring cardiac outcomes.

CLA has been studied extensively in humans for heart health effects, but evidence shows mixed and largely neutral results on key cardiovascular outcomes. While some mechanistic studies suggest anti-inflammatory potential, clinical trials demonstrate no meaningful benefit for blood pressure or endothelial function, and may worsen some markers.

Rapamycin shows promising effects on cardiac structure in animal models and specialized pediatric conditions (cardiac rhabdomyomas), but human efficacy for general heart health remains unproven. One small feline RCT demonstrated reduction in left ventricular wall thickness, but translatable evidence in humans is limited to case reports and mechanistic studies.

D-ribose has plausible mechanistic support and shows positive effects in animal models of heart failure and ischemia, but human efficacy remains unproven. Only one registered human RCT exists (currently ongoing with results not yet published), and no completed human trials demonstrate clinical benefit.

Butyrate shows plausible cardiovascular benefits through multiple mechanistic pathways in humans and animals, but efficacy evidence is inconsistent and limited. One RCT found increased blood pressure with oral butyrate—directly contradicting the theoretical benefit—while observational studies and mechanistic trials suggest potential benefits for hypertension, vascular health, and inflammation when produced endogenously via diet.

Forskolin has not been proven effective for heart health in human trials. While mechanistic studies demonstrate positive inotropic and vasodilatory effects in animal models and isolated cardiac tissue, there are no rigorous human RCTs establishing clinical benefit for cardiovascular outcomes.

Lion's Mane has been studied primarily in animal models for cardiovascular-related effects like cholesterol reduction and endothelial function, with one human cognitive RCT showing minor benefits. Direct evidence for heart health in humans is absent; animal studies show plausible mechanisms but lack human confirmation.

Alpha-GPC shows some promise for heart health based on improved heart rate variability recovery after exercise in one small human study and potential anti-inflammatory effects in animal models, but evidence of direct cardiovascular benefit in humans is limited and contradicted by a large observational study suggesting increased stroke risk.

Bacopa monnieri shows vasodilatory and cardioprotective effects in isolated rat heart studies, but human evidence for heart health is minimal and indirect. One small human RCT showed improved cardiovascular measures as secondary outcomes in a cognitive trial; no dedicated human trials on cardiovascular endpoints exist.

CDP-Choline shows plausible neuroprotective mechanisms in ischemic stroke models, but human evidence for direct cardiac benefit is absent. The available human RCTs focus on cognition and stroke recovery rather than primary heart health outcomes.

Noopept shows neuroprotective effects in a single human RCT for brain ischemia, reducing infarction area by 34.5%, but evidence for general heart health is absent. No studies directly examined cardiovascular outcomes, blood pressure, lipids, or other cardiac parameters.

Piracetam has been studied for heart health primarily in the context of cardiac surgery-related cognitive protection and stroke management, but direct evidence for cardiovascular benefits is limited. Most human evidence addresses cerebral protection during cardiac procedures rather than heart health per se.

Aniracetam has not been studied directly for heart health outcomes. The available evidence is limited to indirect cardiovascular measures in small human studies and animal models, primarily showing effects on autonomic function and cerebral blood flow rather than cardiac endpoints.

Phenylpiracetam shows plausible cardiovascular benefits in animal models, particularly through antiplatelet effects and neuroprotection in ischemia, but human evidence is limited to one small RCT focused on psychiatric comorbidities rather than direct cardiac outcomes. Efficacy for heart health in humans remains unproven.

Uridine has been studied for heart health primarily in the context of HIV treatment side effects and hepatitis C management, with one small human RCT showing improvements in body fat distribution but mixed effects on lipid profiles. Evidence of direct cardiac benefit is limited and mostly indirect.

Vinpocetine shows plausible mechanisms for cardiovascular benefit through anti-inflammatory and vasodilatory effects in animal models and mechanistic studies, but human efficacy for heart health is not proven. Only 5 human RCTs exist among 50 total articles, and efficacy claims remain primarily based on animal data and surrogate markers rather than clinical cardiac outcomes.

Centrophenoxine/meclofenoxate shows plausible cardiovascular benefits in animal models and limited human observational data, but lacks rigorous human RCT evidence demonstrating efficacy for heart health. Current evidence is insufficient to confirm clinical benefit.

Bromantane shows promising cardiovascular effects in animal models, including improved stroke volume and reduced sympathetic activation, but there is no human evidence demonstrating efficacy for heart health. All direct cardiovascular data comes from rodent and cat studies.

Oxiracetam has been studied in multiple human RCTs for post-stroke cognitive decline, but the largest and most recent trials found no statistically significant benefit compared to placebo. Animal studies show some protective effects in cerebrovascular injury models, but human efficacy for heart health specifically remains unproven.

Pramiracetam shows plausible mechanisms for cardiovascular benefit in animal models (antiplatelet activity, improved cerebral blood flow) and one small human observational study suggests cognitive benefits in cerebrovascular disease, but no rigorous human RCTs demonstrate efficacy for heart health specifically.

L-Tyrosine has been studied in small human RCTs for performance under mental fatigue and thermoregulation in older adults, showing modest improvements in specific contexts. However, no evidence directly demonstrates efficacy for general heart health outcomes.

Beta-alanine shows plausible mechanisms for cardiovascular protection through carnosine synthesis and antioxidant pathways, but human evidence for direct heart health benefits is extremely limited and mostly indirect. Most efficacy data comes from animal studies or focuses on exercise performance rather than cardiac outcomes.

BCAAs show mixed evidence for heart health, with observational studies linking elevated circulating BCAAs to increased cardiovascular disease risk, while mechanistic studies suggest potential harm through inflammatory and metabolic pathways. No high-quality human RCTs demonstrate cardiovascular benefits.

L-carnosine shows plausible mechanisms for cardiovascular benefit through antioxidant and anti-inflammatory effects, but human evidence for heart health specifically is limited to 2 small RCTs focused on metabolic markers rather than direct cardiac outcomes. Efficacy for heart health has not been proven in humans.

Leucine's effects on heart health remain largely unproven in humans. While mechanistic studies suggest potential cardiovascular benefits through improved lipid metabolism and reduced macrophage foam-cell formation, human evidence is limited and mixed, with one RCT showing leucine supplementation may actually aggravate cardiovascular disturbances during strenuous exercise.

Tryptophan's effects on heart health are suggested through metabolic pathways but lack direct human clinical evidence of cardiovascular benefit. A Mendelian Randomization meta-analysis found tryptophan itself was not associated with ischemic heart disease, though its metabolite kynurenine showed a modest positive association with heart disease risk.

L-ornithine shows preliminary evidence of reducing physical fatigue in healthy humans through improved lipid and amino acid metabolism, but this finding comes from a single small RCT with limited scope and no independent replication. No evidence directly addresses cardiovascular health outcomes.

Larazotide shows promise for heart health in the context of post-COVID multisystem inflammatory syndrome in children, with one small human RCT demonstrating faster recovery and viral antigen clearance. However, evidence is limited to a single small trial (n=12) and mechanistic animal studies; efficacy for general heart health is not established.

Cortistatin shows promise for heart health through animal studies and small human observational research, but lacks rigorous human RCT evidence. Current data suggests potential benefits in specific cardiovascular conditions, but efficacy in humans remains unproven.

Ghrelin shows cardioprotective effects in mechanistic and animal studies, but human evidence for heart health is limited to small trials and observational data. No large-scale human RCTs demonstrate that ghrelin supplementation improves clinical cardiovascular outcomes.

IGF-1 DES shows plausible mechanisms for cardiovascular protection in animal studies, particularly through enhanced Akt signaling in cardiac muscle and improved vascular smooth muscle cell survival. However, no human clinical trials demonstrate efficacy for heart health.

Nesfatin-1 shows plausible cardiovascular benefits based on multiple observational human studies and animal research, but lacks rigorous RCT evidence proving efficacy for heart health. Most evidence is correlational or mechanistic rather than demonstrating clinical improvement.

Neuropeptide Y is associated with harmful cardiovascular effects in acute coronary events and appears to worsen heart function rather than improve it. Evidence is limited to observational human data and animal studies showing NPY causes coronary vasoconstriction and is linked to worse outcomes post-heart attack.

Orexin-A shows promise for heart health through sympathetic nervous system regulation and blood pressure control, but evidence is limited to one small human RCT and mechanistic studies in animals and narcolepsy patients. Proven efficacy in healthy humans has not been demonstrated.

PACAP-38 shows cardioprotective properties in translational studies and is altered in myocardial infarction patients, but efficacy as a heart health therapeutic remains unproven in humans. One small human RCT and observational studies suggest potential, but lack clinical trial evidence of benefit.

Peptide YY appears in multiple human studies as a marker of satiety and metabolic health, but there is no direct evidence that PYY supplementation or administration improves heart health. Most studies measure PYY levels as a secondary outcome in dietary or metabolic interventions, not as a primary therapy for cardiovascular outcomes.

Pramlintide has not been studied for direct heart health benefits in any of the available abstracts. The only cardiovascular evidence comes from safety assessments showing it does not increase major adverse cardiac events, which is safety data, not efficacy data for heart health.

Thymopentin shows immunomodulatory potential in one human cardiac surgery study, but efficacy for heart health is not proven. The evidence is limited to a single small RCT with indirect immune markers, not direct cardiovascular outcomes.

Calcium supplementation does not improve heart health in general populations; RCT evidence suggests it may slightly increase cardiovascular risk (10-20% higher MI risk), while dietary calcium shows no such association. Efficacy for heart health is not proven.

Manganese supplementation shows promise for reducing cholesterol and improving endothelial function markers in animal models and limited human observational studies, but efficacy in humans remains unproven due to lack of rigorous RCTs and reliance on diabetic/disease models.

Vitamin B3 (nicotinamide and nicotinamide riboside) shows promise for heart health in animal models and early human studies, but human evidence remains limited and mixed. Some studies suggest benefits for blood pressure and cardiac protection, while others raise concerns about high-dose effects on cardiovascular risk.

Ginger shows promise for heart health primarily through animal studies demonstrating anti-inflammatory and antioxidant effects on diabetic cardiomyopathy and lipid profiles. However, human evidence is minimal and indirect—only 6 human RCTs exist, most focused on weight loss and joint pain rather than direct cardiac outcomes, making efficacy for heart health not yet proven in humans.

Lecithin shows consistent effects on lipid metabolism and cholesterol levels in animal and limited human studies, but human efficacy for heart health remains unproven. Most evidence comes from animal models or small observational studies without robust RCT data.

Lutein has not been proven to improve heart health in humans. While mechanistic studies and animal research suggest potential cardiovascular benefits through antioxidant and anti-inflammatory pathways, the human evidence remains limited to surrogate markers (lipid profiles, inflammatory markers) rather than clinical cardiac outcomes.

MCT oil shows promise for heart health in specific rare metabolic disorders (triglyceride deposit cardiomyovasculopathy, long-chain fatty acid oxidation disorders) and may support cardiac function in these populations, but efficacy for general heart health in healthy individuals or common heart disease is not established. Evidence is limited to small human studies in disease populations and animal models.

Zeaxanthin supplementation reduces cardiovascular inflammatory markers (IL-1β, TNF-α) and oxidized LDL in one human RCT, and increases HDL cholesterol in observational studies. However, no human RCTs have demonstrated direct improvements in heart disease outcomes, blood pressure, or cardiovascular events. Current evidence is limited to biomarker changes in healthy or AMD populations.

Burdock root extract reduced cholesterol and body weight in rats, but only one human RCT exists and it was poorly designed (described as animal study despite 'human_rct' label). Efficacy in humans for heart health is plausible but unproven.

Vitamin A has been studied for heart health primarily through observational associations with depression in heart failure patients and lipid metabolism in animal models, but no rigorous human RCTs demonstrate direct cardiovascular benefits. Evidence remains preliminary and mechanistic rather than clinically proven.

DHEA/DHEA-S levels are associated with cardiovascular health in observational studies, but no human RCTs demonstrate that DHEA supplementation improves heart health outcomes. Evidence is mostly correlational and mechanistic.

Caffeine does not demonstrably improve heart health markers. While multiple studies confirm caffeine is generally safe for the heart at typical doses, evidence shows it increases heart rate and blood pressure acutely, and causes tachycardia/palpitations in 6-83% of users depending on dose—the opposite of a heart health benefit.

CJC-1295 has not been studied for heart health in any of the available literature. The three abstracts are limited to doping detection methods and sports misuse reviews with no clinical efficacy data for cardiovascular outcomes.

No clinical evidence demonstrates ipamorelin's efficacy for heart health. The three available abstracts address doping detection, peptide use in sports, and ghrelin receptor imaging—none report actual heart health outcomes or clinical trials in humans.

Selank has been studied for cardiovascular effects in animal models, but evidence shows it produces acute blood pressure decreases rather than cardiovascular benefits. No human studies exist, and findings do not support use for heart health.

PT-141 (bremelanotide) has not been studied for heart health outcomes in any of the available evidence. The abstracts demonstrate the compound causes small transient blood pressure increases in healthy women, which is a cardiovascular risk signal rather than a heart health benefit.

Dihexa has not been studied for heart health. The single available abstract discusses its procognitive and antidementia properties in rodent models; no evidence exists regarding cardiovascular efficacy in any organism.

No human evidence exists demonstrating that Melanotan 1 improves heart health. The three available abstracts are reviews discussing melanocortin receptor mechanisms and porphyria management, with no clinical trials or efficacy data for cardiovascular outcomes.

Cortagen has only been studied in a single small animal study (mice) that examined gene expression changes in heart tissue; no human efficacy data exists for heart health, and no clinical outcomes were measured.

Cardiogen is not meaningfully studied for heart health in humans. The abstracts provided relate to cardiac amyloidosis registries, genetic testing protocols, and one contamination incident from a Rb-82 cardiac PET scan product (CardioGen-82), not a supplement or therapeutic agent for cardiac benefit.

Chonluten has only been studied in vitro in human monocyte cell cultures, showing potential to reduce inflammatory cytokines (TNF and IL-6) when stimulated by bacterial lipopolysaccharide. No human trials or animal studies exist to demonstrate efficacy for heart health.

Bronchogen has not been proven effective for heart health in humans. A single animal study showed that bronchogen stimulated organotypic heart tissue cultures in vitro at very low concentrations, but this preliminary finding has not been replicated in any human studies or even in whole-animal models.

No proven efficacy for heart health. The single available study examined retinal hemodynamics in glaucoma patients, not cardiac outcomes, and found no statistically significant differences between treatment groups.

A single review article from 1996 describes prostatilen's effects on smooth muscle contractility in blood vessels and bladder in cats, but provides no human efficacy data, no quantified results, and no direct evidence that these effects translate to improved heart health.

Saw palmetto has not been studied for heart health in any of the available abstracts. All evidence relates to benign prostatic hyperplasia (BPH) and lower urinary tract symptoms, with no human trials demonstrating cardiac benefits.

DIM has not been studied for heart health in any of the available abstracts. The limited human evidence (1 case report on PSA, not heart health) and in-vitro/animal studies do not demonstrate efficacy for cardiovascular outcomes.

Lactoferrin has not been studied for heart health in humans. The available literature focuses on growth, infection prevention, and brain health, with no direct evidence of cardiovascular benefits.

No evidence supports Fadogia agrestis for heart health. The single available study examined testicular function in rats and found adverse effects on reproductive markers, with no assessment of cardiovascular outcomes.

Echinacea has not been demonstrated to improve heart health in any of the retrieved studies. The compound was studied for immune function and respiratory infections, not cardiovascular outcomes, making the evidence for this specific goal essentially absent.

No human evidence exists for lithium orotate and heart health. A single 1992 review article examined lithium's effects on vascular peptide signaling in isolated pig arteries, which is far removed from proven cardiovascular efficacy in humans.

Pregnenolone is a precursor steroid hormone involved in cholesterol metabolism and steroid biosynthesis, but there is no evidence from human studies demonstrating that pregnenolone supplementation improves heart health or cardiovascular outcomes.

SAMe has not been proven effective for heart health. The abstracts show SAMe is involved in cardiovascular-related metabolic pathways and appears as a biomarker in some heart conditions, but no clinical trials demonstrate that SAMe supplementation improves cardiac outcomes or heart disease.

Peppermint oil has not been studied for heart health in humans. The only human study found was an observational study on IBS and gut microbiota that does not mention peppermint oil, while the other study was conducted in broiler chickens, not humans.

Phosphatidylserine is not demonstrated to improve heart health in any human study presented. The evidence consists almost entirely of mechanistic reviews and observational biomarker studies showing PS involvement in cardiovascular pathology, not therapeutic benefit from PS supplementation.

Huperzine A has not been studied for heart health in any of the available abstracts. All evidence relates to cognitive function, Alzheimer's disease, acetylcholinesterase inhibition, and neurological protection—not cardiovascular outcomes.

9-ME-BC has not been studied for heart health in humans or animals. The two available PubMed abstracts address neuroprotection and cognitive enhancement in neurological models, not cardiovascular outcomes.

DMAE has not been demonstrated to improve heart health in any human studies. The single human RCT examining a DMAE-containing combination supplement showed improvements in exercise capacity and oxygen utilization, but these effects cannot be attributed to DMAE specifically, and no direct cardiac or cardiovascular health outcomes were measured.

Sulbutiamine has not been studied for heart health in humans. The only relevant evidence is an in-vitro study showing neuroprotection in brain neurons under ischemic conditions, which does not directly translate to cardiac efficacy.

L-Glutamine supplementation has not been proven to improve heart health in humans. While the abstracts discuss gut microbiota-derived metabolites related to phenylalanine (phenylacetylglutamine) and heart disease risk, they do not demonstrate that L-Glutamine supplementation reduces cardiovascular disease, improves cardiac function, or prevents adverse cardiac events.

5-HTP has not been studied for heart health outcomes in humans. The available abstracts reveal no clinical trials or human studies demonstrating any direct cardiovascular benefit, efficacy in preventing arrhythmias, or improvement in heart-related conditions.

D-aspartic acid has not been studied for heart health in humans. The only relevant finding is that D-aspartic acid appears as a biomarker in myocardial infarction metabolomics studies, not as a therapeutic intervention. No efficacy data exists for this compound-goal pair.

Abaloparatide is not indicated for heart health and has not been studied as a treatment for cardiovascular disease. The available evidence only examines cardiovascular safety (absence of harm), not efficacy for cardiac benefits.

Adipotide has not been studied directly for heart health. The only reference to Adipotide in these abstracts is a brief comparison showing it performed worse than an alternative nanoparticle formulation (KLA-PTNP) for weight loss in obese mice.

Linaclotide has not been studied for heart health benefits in humans. One mouse model study suggests potential cardiovascular benefits through TMAO reduction, but this is preliminary animal evidence only.

Pemvidutide was not studied for heart health in any of the 50 articles provided. The abstracts discuss other GLP-1 agonists and dual GIP/GLP-1 agonists (tirzepatide, semaglutide, liraglutide) showing cardiovascular benefits, but pemvidutide itself does not appear in any of the abstracts.

Teriparatide was studied in the context of osteoporosis medications and their cardiovascular effects, but the abstracts contain no evidence that teriparatide improves heart health. Multiple studies explicitly examined cardiovascular safety and found teriparatide to be non-harmful or neutral compared to other osteoporosis treatments — safety is not the same as efficacy for heart health.

Thymulin has not been studied for heart health in humans. The available evidence consists only of animal studies examining thymulin's anti-inflammatory effects in lung disease and pulmonary hypertension models, with no direct evidence of cardiac benefit.

Vosoritide has not been studied for heart health benefits in humans. The single relevant study (animal model of diabetic hearts) shows anti-arrhythmic effects in mice, but this does not establish efficacy for heart health in human patients. Clinical evidence is limited to safety observations in achondroplasia patients, where hypotension (a cardiovascular adverse effect) is a known risk.

The provided abstracts do not contain any studies directly investigating C-10 for heart health. The abstracts cover unrelated compounds and interventions (rimegepant for migraine, yoga for heart failure, red wine grape pomace, wheat germ, pitavastatin, semaglutide, natriuretic peptides, and others), but none specifically evaluate C-10 as a compound or supplement for cardiovascular outcomes.

CAAKG (arginine alpha-ketoglutarate) has not been studied for heart health outcomes in any of the 50 available PubMed articles. Evidence is entirely absent for this specific goal.

Sea moss extract has not been proven to improve heart health in humans. Available studies focus on potential mechanisms (anti-inflammatory compounds, omega-3 fatty acids) in isolated seaweed extracts or animal models, but no human clinical trials demonstrate cardiovascular benefits.

No evidence demonstrates that kelp improves heart health. The single human trial found no significant effects on cholesterol or clinical chemistry parameters, and other studies focus on iodine toxicity risks rather than cardiovascular benefits.

No human evidence supports dandelion for heart health. One in vitro study showed dandelion root extract has anti-platelet activity in laboratory conditions, but authors explicitly state further in vivo studies are needed before any cardiovascular benefits can be claimed.

No human evidence supports Yellow Dock for heart health. All three abstracts are reviews discussing mechanistic studies in cell cultures and animal models, with no direct demonstration of cardiovascular benefit in any living organism.

No human evidence exists for manuka honey's effects on heart health. The single available study is a review examining bacterial resistance mechanisms in honey, with no direct assessment of cardiovascular outcomes.

These abstracts do not provide evidence that chlorophyll improves heart health. One study examined chlorophyllin's ability to prevent carcinogen absorption (cancer-related, not cardiac), and the other studied carcinogen metabolism in lactating rats—neither addresses cardiovascular outcomes.

Slippery elm was one ingredient in a multi-supplement weight loss program, but there is no evidence it specifically improved heart health markers. The study does not isolate slippery elm's effects or demonstrate efficacy for this goal.

Custom orthotics (ankle foot orthosis) have not been demonstrated to improve heart health outcomes in the available evidence. The single study examined perceptions of wearing orthotics in peripheral artery disease patients but did not measure cardiovascular endpoints, physical activity improvements, or heart health metrics.